Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Wilson Disease

Interventions

DRUG: ALXN1840
DRUG: Celecoxib

Sponsor

Alexion Pharmaceuticals, Inc.